MANILA, Philippines — The Philippine Chamber of Pharmaceutical Industries Inc. (PCPI) has called for urgent government intervention to bolster domestic drug manufacturing, warning that over-reliance on imported medicines leaves the country vulnerable to global supply shocks. During a forum held on April 28, 2026, the association emphasized that strengthening the local industry is not just an economic goal but a matter of national security.
PCPI Vice President Robert Eugenio, who also serves as a senior executive for Unilab Inc., highlighted how recent events have exposed the fragility of international logistics.
- Supply Chain Vulnerability: The COVID-19 pandemic and ongoing regional conflicts in the Middle East and East Asia have repeatedly disrupted the flow of essential medical inputs.
- Medical Security: Eugenio argued that a self-reliant pharmaceutical base is the only way to ensure Filipinos have a steady supply of life-saving drugs regardless of global instability.
- Tatak Pinoy Alignment: The chamber noted that its goals align with the recently enacted Tatak Pinoy (Proudly Filipino) Law, which promotes high-value domestic production and industrial competitiveness.
To level the playing field for local manufacturers, the PCPI is advocating for several key reforms:
- “Green Lane” Windows: A request for the Food and Drug Administration (FDA) to implement fast-track registration for locally manufactured products to decongest regulatory backlogs.
- Investment Incentives: Legislation that provides tax holidays, duty exemptions, and preferential credit for companies investing in local production facilities.
- Government Procurement: Policies that prioritize locally produced essential medicines for government-funded health programs and public hospitals.
The PCPI pointed out that several Southeast Asian nations have already implemented successful frameworks to nurture their pharmaceutical sectors:
- Thailand: Offers extensive tax incentives through its Board of Investment and maintains strong government procurement preferences for local drugs.
- Indonesia: Combines manufacturing incentives with strict local content requirements for its national health insurance programs.
- Vietnam: Prioritizes technology transfer and streamlined regulatory pathways to help domestic firms move into higher-value medicine production.
“With the right policies, the Philippines can also build a resilient pharmaceutical manufacturing base,” Eugenio emphasized. Beyond public health safety, a robust industry is expected to:
- Generate Quality Jobs: Increase employment in specialized manufacturing, chemistry, and research.
- Attract Long-term Investment: Encourage both local firms and multinationals to build permanent infrastructure in the country.
- Reduce Costs: Potentially lower the retail price of medicines by reducing shipping costs and import duties.
